Benzinga | Apr 14, 2021 08:09AM EDT

Biocept Says Has Received Over 350K Samples For SARS-CoV-2 Testing Since June

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing. These samples are processed using Biocept's RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego.